Document Detail

Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
MedLine Citation:
PMID:  16075416     Owner:  NLM     Status:  MEDLINE    
Use of statins for prevention of coronary heart disease is based on the decrease of serum cholesterol and LDL cholesterol. To better investigate the changes in lipid profile after statin treatment, we propose here to use an analysis of serum by proton nuclear magnetic resonance (NMR) spectroscopy associated with a multivariate analysis of the main spectral components. Sera were obtained from 60 male patients treated for 6 weeks with simvastatin (30 patients) or atorvastatin (30 patients) for who LDL cholesterol decreased by over 45% in all selected patients. Proton nuclear magnetic resonance spectra were obtained and the region of methyl resonance from lipids was separated into six consecutive lines attributed to lipids which were analyzed by principal component analysis (PCA) and clustering by hierarchical cluster analysis (HCA) based on Euclidian distance coupled with the Ward's minimum variance method. PCA and HCA gave a map discriminating the 120 samples into five clusters, three clusters containing samples obtained at baseline and two others containing samples obtained after treatment. Both statins produced a decrease in lower-density lipoprotein components and an increase in higher density lipoprotein components. Patients with a coronary heart disease history could be discriminated after treatment by the increase in the component containing the highest proportion of HDL. Proton NMR spectroscopy of sera coupled with a PCA and an HCA was able to detect variations in the metabolism of lipids resulting from statin treatments.
Laurence Le Moyec; Paul Valensi; Jean-Christophe Charniot; Edith Hantz; Jean-Paul Albertini
Related Documents :
24074036 - Dietary and supplemental antioxidant and anti-inflammatory nutrient intakes and pulmona...
12572626 - A novel therapeutic approach to dyslipidemia.
9530546 - Cerivastatin.
19422526 - Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemo...
11104276 - Effects of amount and source of fat on the rates of lipolysis and biohydrogenation of f...
23660146 - Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  NMR in biomedicine     Volume:  18     ISSN:  0952-3480     ISO Abbreviation:  NMR Biomed     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-31     Completed Date:  2005-12-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8915233     Medline TA:  NMR Biomed     Country:  England    
Other Details:
Languages:  eng     Pagination:  421-9     Citation Subset:  IM    
Laboratoire Biomoceti, UMR CNRS 7033, Université Paris-13, Bobigny, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / therapeutic use*
Cholesterol / blood
Cluster Analysis*
Coronary Disease / prevention & control
Heptanoic Acids / therapeutic use*
Hyperlipidemias / blood,  drug therapy*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Middle Aged
Multivariate Analysis
Nuclear Magnetic Resonance, Biomolecular
Principal Component Analysis*
Pyrroles / therapeutic use*
Reproducibility of Results
Simvastatin / therapeutic use*
Reg. No./Substance:
0/Antilipemic Agents; 0/Heptanoic Acids; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Pyrroles; 110862-48-1/atorvastatin; 57-88-5/Cholesterol; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy.
Next Document:  Proteomic identification of putative plasmodesmatal proteins from Chara corallina.